A retrospective cohort study to determine impact of diagnostic and antimicrobial stewardship on time-to-appropriate therapy and clinical outcomes of patients with multi-drug resistant pseudomonas infections utilizing novel beta-lactam/beta-lactamase inhibitors
Latest Information Update: 15 Dec 2020
At a glance
- Drugs Avibactam/ceftazidime (Primary) ; Ceftolozane/tazobactam (Primary)
- Indications Pseudomonal infections
- Focus Therapeutic Use
- 15 Dec 2020 New trial record
- 25 Oct 2020 Results presented at the IDWeek 2020